ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.11 Million GBP | 36.63% |
| 2022 | -11.22 Million GBP | 13.06% |
| 2021 | -12.91 Million GBP | 10.38% |
| 2020 | -14.4 Million GBP | 21.18% |
| 2019 | -18.28 Million GBP | 10.28% |
| 2018 | -20.37 Million GBP | -2.46% |
| 2017 | -19.88 Million GBP | -44.91% |
| 2016 | -13.72 Million GBP | -32.04% |
| 2015 | -10.39 Million GBP | -30.43% |
| 2014 | -7.96 Million GBP | -12.43% |
| 2013 | -7.08 Million GBP | -2.96% |
| 2012 | -6.88 Million GBP | -3.27% |
| 2011 | -6.66 Million GBP | -7.2% |
| 2010 | -6.21 Million GBP | -33.2% |
| 2009 | -4.66 Million GBP | 32.24% |
| 2008 | -6.88 Million GBP | -15.51% |
| 2007 | -5.96 Million GBP | 12.67% |
| 2006 | -6.82 Million GBP | -104.71% |
| 2005 | -3.33 Million GBP | -166.24% |
| 2004 | -1.25 Million GBP | 75.68% |
| 2003 | -5.15 Million GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.65 Million GBP | 41.92% |
| 2024 Q2 | -1.65 Million GBP | 0.0% |
| 2023 FY | -7.11 Million GBP | 36.63% |
| 2023 Q4 | -2.84 Million GBP | -100.0% |
| 2023 Q2 | -4.27 Million GBP | -100.0% |
| 2023 Q1 | -2.13 Million GBP | 58.57% |
| 2023 Q3 | -1.42 Million GBP | 66.76% |
| 2022 Q4 | -5.15 Million GBP | -100.0% |
| 2022 Q3 | -2.57 Million GBP | 57.51% |
| 2022 FY | -11.22 Million GBP | 13.06% |
| 2022 Q1 | -3.03 Million GBP | 41.34% |
| 2022 Q2 | -6.07 Million GBP | -100.0% |
| 2021 Q1 | -3.9 Million GBP | 55.26% |
| 2021 FY | -12.91 Million GBP | 10.38% |
| 2021 Q4 | -5.17 Million GBP | -100.0% |
| 2021 Q3 | -2.58 Million GBP | 66.91% |
| 2021 Q2 | -7.81 Million GBP | -100.0% |
| 2020 Q2 | -5.77 Million GBP | -102.24% |
| 2020 Q4 | -8.73 Million GBP | -100.83% |
| 2020 Q1 | -2.85 Million GBP | 46.19% |
| 2020 FY | -14.4 Million GBP | 21.18% |
| 2020 Q3 | -4.35 Million GBP | 24.63% |
| 2019 Q3 | -5.3 Million GBP | -37.93% |
| 2019 Q1 | -3.84 Million GBP | 21.77% |
| 2019 FY | -18.28 Million GBP | 10.28% |
| 2019 Q4 | -5.3 Million GBP | 0.0% |
| 2019 Q2 | -3.84 Million GBP | 0.0% |
| 2018 Q3 | -4.91 Million GBP | 6.77% |
| 2018 Q2 | -5.27 Million GBP | 0.0% |
| 2018 Q1 | -5.27 Million GBP | -21.71% |
| 2018 FY | -20.37 Million GBP | -2.46% |
| 2018 Q4 | -4.91 Million GBP | 0.0% |
| 2017 Q2 | -4.81 Million GBP | 0.0% |
| 2017 FY | -19.88 Million GBP | -44.91% |
| 2017 Q1 | -4.81 Million GBP | -15.6% |
| 2017 Q3 | -4.33 Million GBP | 10.05% |
| 2017 Q4 | -4.33 Million GBP | 0.0% |
| 2016 Q1 | -2.69 Million GBP | -0.86% |
| 2016 FY | -13.72 Million GBP | -32.04% |
| 2016 Q4 | -4.16 Million GBP | 0.0% |
| 2016 Q3 | -4.16 Million GBP | -54.53% |
| 2016 Q2 | -2.69 Million GBP | 0.0% |
| 2015 Q1 | -2.45 Million GBP | -12.49% |
| 2015 Q4 | -2.67 Million GBP | 0.0% |
| 2015 Q3 | -2.67 Million GBP | -8.95% |
| 2015 Q2 | -2.45 Million GBP | 0.0% |
| 2015 FY | -10.39 Million GBP | -30.43% |
| 2014 Q1 | -1.74 Million GBP | 6.93% |
| 2014 FY | -7.96 Million GBP | -12.43% |
| 2014 Q4 | -2.18 Million GBP | 0.0% |
| 2014 Q3 | -2.18 Million GBP | -24.88% |
| 2014 Q2 | -1.74 Million GBP | 0.0% |
| 2013 Q4 | -1.87 Million GBP | 0.0% |
| 2013 Q3 | -1.87 Million GBP | 0.0% |
| 2013 FY | -7.08 Million GBP | -2.96% |
| 2012 FY | -6.88 Million GBP | -3.27% |
| 2011 FY | -6.66 Million GBP | -7.2% |
| 2010 FY | -6.21 Million GBP | -33.2% |
| 2009 FY | -4.66 Million GBP | 32.24% |
| 2008 FY | -6.88 Million GBP | -15.51% |
| 2007 FY | -5.96 Million GBP | 12.67% |
| 2006 FY | -6.82 Million GBP | -104.71% |
| 2005 FY | -3.33 Million GBP | -166.24% |
| 2004 FY | -1.25 Million GBP | 75.68% |
| 2003 FY | -5.15 Million GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -466.481% |
| Skye Bioscience, Inc. | -13.67 Million USD | 47.959% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 108.693% |
| Nascent Biotech, Inc. | -2.22 Million USD | -219.076% |
| Qrons Inc. | -643.67 Thousand USD | -1005.368% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 8.535% |
| CSL Limited | 3.7 Billion USD | 100.192% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 60.133% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -41.045% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -935.738% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 87.182% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1612.481% |
| Rebus Holdings, Inc. | -664 Thousand USD | -971.536% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -432.787% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1726.373% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 55.166% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 90.089% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 244.767% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -2618.492% |
| SQZ Biotechnologies Company | -75.82 Million USD | 90.617% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -149.605% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -363.201% |
| Mesoblast Limited | -84.14 Million USD | 91.545% |
| Marizyme, Inc. | -34.08 Million USD | 79.127% |
| Genus plc | 6.4 Million USD | 211.172% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 173.031% |
| Pharming Group N.V. | -4.87 Million USD | -45.813% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -258.171% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -663.92% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 14.79% |
| ContraFect Corporation | -56.88 Million USD | 87.493% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -56.211% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -407.493% |
| IMV Inc. | -38.67 Million USD | 81.601% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -158.648% |
| MultiCell Technologies, Inc. | -722.81 USD | -984252.734% |
| ONE Bio Corp. | 13.68 Million USD | 152.004% |
| Accustem Sciences Inc. | -3.74 Million USD | -89.915% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 87.939% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -1372.896% |
| Q BioMed Inc. | -3.44 Million USD | -106.494% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 300.989% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -170.787% |
| Biomind Labs Inc. | -1 Million USD | -604.732% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 87.057% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -145.239% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -7.024% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -281.63% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -23654.674% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -268.155% |
| GB Sciences, Inc. | -1.42 Million USD | -400.877% |
| Alpha Cognition Inc. | -9.7 Million USD | 26.692% |
| HST Global, Inc. | -140.9 Thousand USD | -4949.43% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -532.497% |
| Halberd Corporation | -75.05 Thousand USD | -9380.346% |
| Enzolytics Inc. | -2.14 Million USD | -231.115% |
| Agentix Corp. | -1.37 Million USD | -418.678% |
| Resverlogix Corp. | -12.74 Million USD | 44.192% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -124.57% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 98.326% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -581.513% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -143.711% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -350.5% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -108.959% |
| AVAX Technologies, Inc. | 6.69 Million USD | 206.307% |
| Zenith Capital Corp. | -8.94 Million USD | 20.441% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.289% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -40741.513% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -189.779% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -4048.457% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -254.906% |
| Kadimastem Ltd | -3.04 Million USD | -134.027% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -623.03% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -3820.434% |
| LadRx Corporation | -3.82 Million USD | -86.08% |
| Cell Source, Inc. | -4.32 Million USD | -64.496% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -935.738% |
| NovAccess Global Inc. | -2.46 Million USD | -188.435% |
| Affymax, Inc. | -15.04 Million USD | 52.712% |
| Itoco Inc. | -919.14 Thousand USD | -674.093% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -67.869% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -535.836% |
| Mobile Lads Corp. | -554.55 Thousand USD | -1183.022% |
| CytoDyn Inc. | -18.05 Million USD | 60.599% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -28167.779% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -3132.945% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -1159.91% |
| SYBLEU INC | -149.18 Thousand USD | -4669.406% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -291.726% |
| International Stem Cell Corporation | -663 Thousand USD | -973.152% |
| Bioxytran, Inc. | -3.82 Million USD | -86.249% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -13416.337% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -34880.334% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 80.381% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -339.74% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -866.929% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -128.705% |
| Neutra Corp. | -229.48 Thousand USD | -3000.407% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 59.433% |
| PureTech Health plc | -146.19 Million USD | 95.133% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 66.893% |
| IXICO plc | -1.43 Million USD | -395.129% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 25.034% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 94.159% |
| CSL Limited | 3.81 Billion USD | 100.187% |
| Cellectis S.A. | -108.85 Million USD | 93.464% |